drugset / Trial / NCT06633042
The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD
Phase 1
Not yet recruiting
18 enrolled
Bioray Laboratories
Wenzhou Medical University Affiliated Ophthalmology Hospital · collab
NaSequentialOpen-labelTreatment
Summary
This is an open label, Multi-center，dose-escalation study in up to 18 participants with refractory NMOSD. This study aims to evaluate the safety and efficacy of universal CAR-T Cells targeting BCMA in the Treatment of refractory NMOSD.
Timeline
- Start
- 2024-11-25
- Primary completion
- 2025-10-12
- Completion
- 2025-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Universal BCMA-CD19 CART | Cell therapy | 1 cells/kg | — |
| Subject | Universal BCMA-CD19 CART | Cell therapy | 2 cells/kg | — |
| Subject | Universal BCMA-CD19 CART | Cell therapy | 4 cells/kg | — |